Hypomagnesemia in Continuous Ambulatory Peritoneal Dialysis Patients Dialyzed with a Low-Magnesium Peritoneal Dialysis Solution

1995 ◽  
Vol 15 (1) ◽  
pp. 61-64 ◽  
Author(s):  
A. Ahsan Ejaz ◽  
Andrew P. McShane ◽  
Vasant C. Gandhi ◽  
David J. Leehey ◽  
Todd S. Ing

Objective Previous studies have shown a decrease in serum magnesium (Mg) concentration when continuous ambulatory peritoneal dialysis (CAPD) patients previously maintained on a 1.0 –1.2 mEq/L Mg peritoneal dialysis solution (PDS) were dialyzed with a 0.5 mEq/L Mg PDS. However, the prevalence of hypomagnesemia in CAPD patients dialyzed with low-Mg PDS is unknown. Design A retrospective study to determine the prevalence of hypomagnesemia and the factors associated with its occurrence in CAPD patients dialyzed using a 0.5 mEq/L Mg PDS. Setting A CAPD unit in a large Veterans Affairs Hospital. Patients All our CAPD patients (33) enrolled over a 52month period. Results All patients had serum magnesium levels higher than 1.25 mEq/L prior to use of low-Mg PDS. Hypomagnesemia (serum Mg < 1.25 mEq/L) developed in 21/33 patients (64%) when a 0.5 mEq/L Mg PDS was employed. Hypomagnesemia developed a mean of 8.2 months after beginning treatments. The duration of dialysis and the number of episodes of peritonitis did not differ between patients with and those without hypomagnesemia. Serum albumin levels were significantly lower in patients with hypomagnesemia (2.5±0.12 g/dL vs 3.2±0.12, p < 0.01). Magnesium supplements were given to 13 patients; following this therapy, serum magnesium values became normal. Conclusions CAPD patients dialyzed with a 0.5 mEq/L Mg PDS may develop a considerable fall in serum magnesium level and may require magnesium supplements in order to restore normal serum values.

1983 ◽  
Vol 3 (2) ◽  
pp. 63-65 ◽  
Author(s):  
Karl D. Nolph Barbara ◽  
Prowant Kenneth D ◽  
Serkes Linda Morgan ◽  
Betty Baker Chaim ◽  
Chary Tan Kathy Gham ◽  
...  

Four co-operating centers evaluated the effects of a new dialysis solution containing 40 mEq/1 of lactate and 0.5 mEq/1 of magnesium on serum total CO2 and magnesium concentrations. The new solution yielded significant increases in serum CO2 and decreases in serum magnesium compared to the standard (35 mEq/1 of lactate and 1.5 mEq/1 of magnesium) solution.


2007 ◽  
Vol 5 (2) ◽  
pp. 102 ◽  
Author(s):  
Hyun-Wook Kim ◽  
Jae Hyun Chang ◽  
Sun Young Park ◽  
Sung Jin Moon ◽  
Dong Ki Kim ◽  
...  

1986 ◽  
Vol 20 (9) ◽  
pp. 697-700 ◽  
Author(s):  
Paul C. Walker ◽  
Ralph E. Kaufmann ◽  
Neil Massoud

The compatibility of cefazolin and gentamicin in fluid commonly used for continuous ambulatory peritoneal dialysis (CAPD) was studied. Five admixtures containing cefazolin (75 mg/L and 150 mg/L) and gentamicin (8 mg/L), alone and in combination, were prepared in 1.5% dextrose peritoneal dialysis solution. Solutions were stored for 48 hours at 4°C, 26°C, and 37°C; aliquots for drug assay were obained at 0, 4, 8, 24, and 48 hours. HPLC and immunofluorescent assays were used to determine cefazolin and gentamicin concentrations, respectively. The cefazolin and gentamicin concentration changes over the study period did not reach statistical significance. Maximal cefazolin and gentamicin losses (12 and 7 percent of the initial concentrations, respectively) were observed at 48 hours in solutions stored at 37°C. No significant differences in concentration changes were observed between combination solutions and solutions containing either cefazolin or gentamicin alone. Cefazolin and gentamicin, alone or in combination, are compatible for at least 48 hours in CAPD solutions.


2017 ◽  
Vol 45 (1-3) ◽  
pp. 110-117 ◽  
Author(s):  
Shihming Tsai ◽  
Huiping Zhao ◽  
Bei Wu ◽  
Li Zuo ◽  
Mei Wang

Background/Aims: Both hypomagnesemia and hypermagnesemia have been associated with cardiovascular diseases, bone diseases, and mortality in dialysis patients. We aimed to investigate the prevalence of and influencing factors for abnormal serum Mg levels in patients on peritoneal dialysis (PD). Methods: A cross-sectional study in Peking University People’s Hospital recorded the demographic information, clinical characteristics, and laboratory data. Data were assessed and compared with the results from 2 other studies in China. Results: Of 180 enrolled PD patients, the primary diseases were glomerulonephritis (38.3%) and diabetic nephropathy (38.3%). Mean serum Mg concentration was 1.02 ± 0.16 mmol/L; 67% had normal serum Mg concentrations, and 33% had hypermagnesemia. Conclusions: Hypermagnesemia is likely to occur in patients with higher serum phosphate, lower intact parathyroid hormone, and lower high-sensitivity C-reactive protein levels. Serum Mg level distributions in PD patients vary throughout China, may have different potential causes (such as geographical location and dietary habits) and should be further studied.


1992 ◽  
Vol 12 (4) ◽  
pp. 359-364 ◽  
Author(s):  
Genevieve Krack ◽  
Giusto Viglino ◽  
Pier Luigi Cavalli ◽  
Carmen Gandolfo ◽  
Giuseppe Magliano ◽  
...  

Reports in the literature have linked a low phosphatidylcholine content in continuous ambulatory peritoneal dialysis {CAPD) effluent to ultrafiltration loss. Clinical evidence suggests that adding phosphatidylcholine to the dialysis solution enhances ultrafiltration. A clinical study has been designed to clarify the effect of phosphatidylcholine on ultrafiltration in CAPD patients with normal ultrafiltration. A weekly measurement of the peritoneal equilibration test was conducted per patient in the hospital. A comparison between the control dialysis solution {three-week period) and the phosphatidylcholine premixed solution {three-week period) was performed on a total of 12 patients. This study shows that a phosphatidylcholine premixed dialysis solution significantly enhances ultrafiltration. Since ultrafiltration per osmotic driving force (mUg glucose) is enhanced, the patient's glucose load per day is reduced to achieve equal ultrafiltration. In the presence of phosphatidylcholine, peritoneal permeability remained unchanged, as indicated by membrane transport characteristics. No side effects were observed.


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii552-iii552
Author(s):  
Sandra Beltrán ◽  
Belén Vizcaino ◽  
Pablo Molina ◽  
Ana Avila ◽  
Marco Montomoli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document